These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 17239324

  • 21. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
    Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Charu V.
    J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515
    [Abstract] [Full Text] [Related]

  • 22. [Meta-analysis of phase III studies with palonosetron in the prevention of vomiting induced by moderately emetogenic chemotherapy].
    Di Maio M, Gallo C, Perrone F.
    Tumori; 2008 Sep; 94(2):suppl 14-22. PubMed ID: 18564621
    [No Abstract] [Full Text] [Related]

  • 23. An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting.
    Fabi A, Malaguti P.
    Expert Opin Pharmacother; 2013 Apr; 14(5):629-41. PubMed ID: 23414148
    [Abstract] [Full Text] [Related]

  • 24. [Experience with the use of palonosetron (onicit) in patients with solid tumors receiving cytostatic therapy].
    Vladimirova LY, Mitashok IS, Storozhakova AE, Kalabanova EA, Svetitskaya YV, Kabanov SN.
    Vopr Onkol; 2015 Apr; 61(4):653-5. PubMed ID: 26571839
    [Abstract] [Full Text] [Related]

  • 25. Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
    Kim KI, Lee DE, Cho I, Yoon JH, Yoon SS, Lee HS, Oh JM.
    Ann Pharmacother; 2012 Dec; 46(12):1637-44. PubMed ID: 23170032
    [Abstract] [Full Text] [Related]

  • 26. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group.
    Fauser AA, Duclos B, Chemaissani A, Del Favero A, Cognetti F, Diaz-Rubio E, Cortes-Funes H, Conte PF, Dressler H.
    Eur J Cancer; 1996 Aug; 32A(9):1523-9. PubMed ID: 8911112
    [Abstract] [Full Text] [Related]

  • 27. Prevention of emesis from multiple-day and high-dose chemotherapy regimens.
    Navari RM.
    J Natl Compr Canc Netw; 2007 Jan; 5(1):51-9. PubMed ID: 17239326
    [Abstract] [Full Text] [Related]

  • 28. The current status of the use of palonosetron.
    Navari R.
    Expert Opin Pharmacother; 2013 Jul; 14(10):1281-4. PubMed ID: 23647207
    [Abstract] [Full Text] [Related]

  • 29. Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
    Xiao Y, Liu J, Liu YC, Huang XE, Guo JX, Wei W.
    Asian Pac J Cancer Prev; 2014 Jul; 15(9):3951-4. PubMed ID: 24935579
    [Abstract] [Full Text] [Related]

  • 30. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.
    Seol YM, Kim HJ, Choi YJ, Lee EM, Kim YS, Oh SY, Koh SJ, Baek JH, Lee WS, Joo YD, Lee HG, Yun EY, Chung JS.
    Support Care Cancer; 2016 Feb; 24(2):945-952. PubMed ID: 26265119
    [Abstract] [Full Text] [Related]

  • 31. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials.
    del Giglio A, Soares HP, Caparroz C, Castro PC.
    Cancer; 2000 Dec 01; 89(11):2301-8. PubMed ID: 11147601
    [Abstract] [Full Text] [Related]

  • 32. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients.
    Aapro MS, Macciocchi A, Gridelli C.
    J Support Oncol; 2005 Dec 01; 3(5):369-74. PubMed ID: 16218261
    [Abstract] [Full Text] [Related]

  • 33. Review of palonosetron: emerging data distinguishing it as a novel 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting.
    Saito M, Tsukuda M.
    Expert Opin Pharmacother; 2010 Apr 01; 11(6):1003-14. PubMed ID: 20307224
    [Abstract] [Full Text] [Related]

  • 34. Palonosetron versus other 5-HT₃ receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States.
    Craver C, Gayle J, Balu S, Buchner D.
    J Med Econ; 2011 Apr 01; 14(3):341-9. PubMed ID: 21542674
    [Abstract] [Full Text] [Related]

  • 35. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update.
    Patel P, Robinson PD, Thackray J, Flank J, Holdsworth MT, Gibson P, Orsey A, Portwine C, Freedman J, Madden JR, Phillips R, Sung L, Dupuis LL.
    Pediatr Blood Cancer; 2017 Oct 01; 64(10):. PubMed ID: 28453189
    [Abstract] [Full Text] [Related]

  • 36. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer.
    Navari RM.
    Future Oncol; 2010 Jul 01; 6(7):1073-84. PubMed ID: 20624119
    [Abstract] [Full Text] [Related]

  • 37. Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy.
    Hamadani M, Awab A, Chaudhary L, Tfayli A.
    J Oncol Pharm Pract; 2006 Jun 01; 12(2):67-8. PubMed ID: 16984743
    [No Abstract] [Full Text] [Related]

  • 38. Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials.
    Chow R, Tsao M, Chiu L, Popovic M, Milakovic M, Lam H, DeAngelis C.
    Ann Palliat Med; 2018 Apr 01; 7(2):221-233. PubMed ID: 29764184
    [Abstract] [Full Text] [Related]

  • 39. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
    Hajdenberg J, Grote T, Yee L, Arevalo-Araujo R, Latimer LA.
    J Support Oncol; 2006 Oct 01; 4(9):467-71. PubMed ID: 17080735
    [Abstract] [Full Text] [Related]

  • 40. Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting.
    Ruhlmann C, Herrstedt J.
    Expert Rev Anticancer Ther; 2010 Feb 01; 10(2):137-48. PubMed ID: 20131990
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.